17 May 2024


After Covishield, new study finds side effects in Covaxin recipients

A recent study published in Springer Nature revealed that over 30% of Covaxin recipients reported "adverse events of special interest" (AESI).

15 Aug 2022

United Kingdom

Bharat Biotech completes third-phase of intranasal COVID-19 vaccine trials

The manufacturing body of the made-in-India Covaxin is only steps away from releasing its intranasal vaccine for the virus.

Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension

The Ministry of External Affairs (MEA) on Friday denied reports that it had asked Bharat Biotech to address issues to avoid the cancellation of the World Health Organization's (WHO) emergency approval for its COVAXIN.

DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years

In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years.

COVAXIN likely to get approval for children above 2yrs: Report

Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.

COVAXIN, Covishield will now be available in hospitals and clinics

The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.

03 Jan 2022


COVAXIN supply to be increased as teens get COVID-19 vaccines

Pharmaceutical firm Bharat Biotech on Monday said it plans to increase the supply of its COVID-19 vaccine COVAXIN to up to eight crore doses a month, starting February.

24 Nov 2021


COVAXIN found 50% effective against COVID-19 in first real-world study

COVAXIN, India's indigenous coronavirus vaccine, is 50% effective against symptomatic COVID-19, the first real-world study of its effectiveness suggests.

UK to add COVAXIN to approved vaccines from November 22

The government of United Kingdom has said that India's coronavirus vaccine COVAXIN will be added to its list of approved vaccines for international travelers.

07 Nov 2021


COVID-19: India reports 11K new cases, 526 more deaths

India on Sunday reported nearly 11,000 new COVID-19 cases with an active caseload of 1.44 lakh, the lowest in 260 days.

COVAXIN gets WHO approval for emergency use listing

The World Health Organization (WHO) on Wednesday granted Emergency Use Listing (EUL) to COVAXIN.

01 Nov 2021


Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers

Australia on Monday accepted India's indigenous vaccine, COVAXIN, as a "recognized" vaccine for the purpose of travel to the country.

COVAXIN under review; may get WHO recommendation in 24 hours

A technical advisory group of the World Health Organization (WHO) is reviewing data on COVAXIN and may recommend emergency use approval for the vaccine within 24 hours, an official said.

19 Oct 2021


Vaccination for children can wait as trial still underway: Expert

India's top virologist Dr. Gagandeep Kang has said that there should not be any hurry to vaccinate children against COVID-19 as vaccine trials are ongoing and immunogenicity data is still awaited.

19 Oct 2021


Cannot cut corners, thorough evaluation needed for COVAXIN EUL: WHO

The World Health Organization (WHO) Monday clarified the reason behind the delay in COVAXIN's emergency use listing (EUL), stating that it is expecting more information from Bharat Biotech on its COVID-19 vaccine.

WHO expert panel to discuss COVAXIN approval in meet today

COVAXIN, India's indigenous vaccine against the coronavirus, will likely receive the much-awaited approval from the World Health Organization (WHO) this month.

COVAXIN trial data for children aged 2-18 submitted to DCGI

Bharat Biotech has reportedly submitted trial data of its COVID-19 vaccine, COVAXIN, for children aged under 18 years to the Drugs and Comptroller General of India (DCGI).

Decision on EUL of COVAXIN in October, says WHO

A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN will be made in October, the World Health Organization has said.

28 Sep 2021

Mansukh Mandaviya

India administers over 1 crore COVID-19 vaccines for 5th time

India administered more than one crore coronavirus vaccine doses on Monday, taking the cumulative number of administered doses in the country to above 86 crore, according to the Union Health Ministry.

21 Sep 2021


COVAXIN for children: Bharat Biotech completes Phase 2/3 trials

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said.

Bharat Biotech awaits feedback from WHO for COVAXIN's EUL

Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine COVAXIN to the World Health Organization for EUL and is awaiting feedback from the global health watchdog.

WHO nod for COVAXIN expected by September-end: Report

NITI Aayog member Dr. VK Paul has said that India's indigenous COVID-19 vaccine COVAXIN's trial data looked promising, and the vaccine could soon get emergency-use approval from the World Health Organization (WHO) soon.

WHO seeks more data from Sputnik V makers for EUL

The World Health Organization has sought some more data from Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, developer of COVID-19 vaccine Sputnik V for according Emergency Use Listing status to the jab.

Single COVAXIN dose might be enough for those previously infected

A single dose of Bharat Biotech's COVAXIN in previously COVID-19-infected individuals elicits a similar antibody response as obtained with two doses of the vaccine in those without a previous history of the disease, according to an ICMR study.

COVID-19 vaccine for children likely by September, says ICMR-NIV chief

India will likely have a COVID-19 vaccine for children by next month, Dr. Priya Abraham said in an interview.

India's drug regulator approves study on mixing Covishield, COVAXIN jabs

The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.

08 Aug 2021


Mixing of Covishield, COVAXIN vaccines gives positive results: ICMR study

A study conducted by the Indian Council of Medical Research (ICMR) has indicated that mixing and matching of COVID-19 vaccines Covishield and COVAXIN can yield better results.

Government expert panel recommends conducting trials on mixing Covishield, COVAXIN

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses.

28 Jul 2021


As vaccination pace remains slow, Centre may reduce private quota

The Centre may soon reduce the 25% quota of COVID-19 vaccine supply for private facilities for their failure to pick up the earmarked quota.

26 Jul 2021

Health & Wellness

India to miss July vaccination target over low COVAXIN supply

India will miss its target to give out over 500 million (50 crore) coronavirus vaccine shots by the end of July, mainly because of low supplies of COVAXIN, its only indigenous jab so far.

24 Jul 2021


Bharat Biotech ends its Brazil agreement. What went wrong?

Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.

24 Jul 2021

Randeep Guleria

COVID-19 vaccines for children likely by September, says AIIMS chief

India will likely have its first coronavirus vaccine for children by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).

23 Jul 2021


Bharat Biotech commits to supply 500mn COVAXIN doses to Centre

Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.

17 Jul 2021


Government to procure 66 crore doses of Covishield, COVAXIN

The Centre has placed an order to procure 66 crore doses of Covishield and COVAXIN to be supplied between August and December this year, at a revised price of Rs. 205 and Rs. 215 per dose, respectively, excluding taxes, official sources said.

28 May 2021

Bharat Biotech

Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance

Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.

09 Jul 2021

Zydus Cadila

Zydus vaccine for 12-18-year-olds from September, says expert panel chief

Coronavirus vaccination for children with the Zydus Cadila vaccine will start by September, said Dr. NK Arora, the chief of National Expert Group on Vaccine Administration.

03 Jul 2021


COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech

COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.

Seven EU nations, Switzerland approve India-made Covishield for 'Green Pass'

The European Union's (EU) Digital COVID Certificate framework to allow easier, restriction-free movement of vaccinated travelers within European countries—excluding India-made Covishield and COVAXIN vaccines—comes into force on Thursday.

30 Jun 2021


Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil

Hyderabad-based pharmaceutical company Bharat Biotech denied any wrongdoing on its part after Brazil suspended a $324 million contract for doses of its COVID-19 vaccine COVAXIN.

30 Jun 2021


COVAXIN effectively neutralizes the Delta variant, top US body says

Through the coronavirus pandemic, we have seen many variants emerge and cause fatal outbreaks across the globe.

23 Jun 2021


COVAXIN for children aged 2-18 by September, says AIIMS chief

India's first coronavirus vaccine for children could be ready by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).

22 Jun 2021


COVAXIN 77.8% effective; government panel reviews Phase III trial data

COVAXIN, the COVID-19 vaccine developed by Bharat Biotech, has been found 77.8% effective against the viral disease, Phase III trial data reportedly revealed.

Bharat Biotech submits COVAXIN phase-3 trial data, review meet today

Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).

16 Jun 2021


Calf serum absent in COVAXIN, involved in development, government clarifies

COVAXIN, the indigenous COVID-19 vaccine produced by Bharat Biotech, does not contain calf serum, the Union Health Ministry clarified on Wednesday.

11 Jun 2021


FDA rejects emergency-use approval of Bharat Biotech's COVAXIN

The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN.

10 Jun 2021


After updating vaccine policy, Centre may renegotiate Covishield, COVAXIN prices

After India's COVID-19 vaccination policy was updated this week, the central government is likely to renegotiate prices for vaccines, a report suggested.

AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN.

05 Jun 2021


Deck cleared for import of COVAXIN, Sputnik V into Brazil

Brazil has cleared the proposal to import Bharat Biotech's COVID-19 vaccine, COVAXIN, and Russia's COVID-19 vaccine Sputnik V into the South American country.

03 Jun 2021


COVAXIN trials on children aged 2-18 begin at AIIMS-Patna

The All India Institute of Medical Sciences (AIIMS) in Patna has begun the clinical trials for COVAXIN on children, reports say.

Health Ministry thrashes reports about 'missing' COVAXIN doses

The Health Ministry has slammed news about unaccounted COVAXIN doses as "unfound media reports" adding that these reports are incorrect and not supported by full information on the matter.

28 May 2021


4 crore COVAXIN doses missing? Mismatch in production, availability reported

Even as India is facing an acute vaccine shortage, a report indicates that there is a mismatch in the number of doses of COVAXIN produced and the number of doses administered.

28 May 2021

Manish Sisodia

Second drive-through vaccination camp inaugurated in Delhi

A two-day drive-through vaccination camp for people in the age group of 18-44 years was inaugurated by Delhi Deputy Chief Minister Manish Sisodia in Saket on Thursday, officials said.

27 May 2021

Uttar Pradesh

1st dose Covishield, 2nd dose COVAXIN: Vaccination blunder in UP

In a grave oversight, a group of villagers in Uttar Pradesh received two shots of two different vaccines: COVAXIN and Covishield (both two-dose vaccines).

Need more information to give EUL to COVAXIN: WHO

The World Health Organization (WHO) has said that more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN.

COVAXIN trials on children are expected to begin in June

Bharat Biotech, the pharmaceutical firm behind India's first indigenous COVID-19 vaccine COVAXIN, may begin trials on children in June and is expecting to receive the license in the third quarter of this year.

19 May 2021


Karnataka targets vaccinating eligible population by 2021 end

The Karnataka government has set a goal to vaccinate all eligible people in the state by November end against coronavirus.

16 May 2021


COVAXIN, Covishield effective, but produce fewer antibodies against B.1.617: Report

According to a series of early reports authored by scientists at the Indian Council of Medical Research (ICMR), COVAXIN and Covishield—vaccines deemed effective at generating an immune response against COVID-19—appear to generate only half as many antibodies against the B.1.617 variant.

13 May 2021

Bharat Biotech

COVAXIN approved for Phase 2/3 trials on 2-18-year-olds

India's apex drug regulator has granted permission for conducting the Phase II/III clinical trial of Bharat Biotech's COVAXIN in the age group of 2 to 18 years, the Union Health Ministry said on Thursday. The trial will be conducted on 525 healthy volunteers.

12 May 2021


Government-owned BIBCOL to produce 2 crore COVAXIN doses every month

To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr.

12 May 2021

Manish Sisodia

Bharat Biotech has refused additional COVAXIN doses to Delhi: Sisodia

Deputy Chief Minister Manish Sisodia on Wednesday said that Hyderabad-based Bharat Biotech has informed the Delhi government that it cannot provide "additional" doses of COVAXIN to the national capital.